Japan · Advertising framework
Podcast advertising and host-read promotions for medical treatments and services in Japan
General market orientation, not campaign clearance. Research scope and dates
Product and service rules
Medical and dental advertising is not ordinary consumer promotion
Regulator guidance
Medical Care Act advertising rules cover medical and dental practice, hospitals and clinics, including qualifying websites. Check the permitted-information rules and any website exemption conditions, alongside prohibitions on false or exaggerated claims and misleading superiority.
Sources: MHLW: advertising restrictions for hospitals and clinics
Testimonials and treatment images have specific restrictions
Regulator guidance
Subjective patient testimonials about treatment content or effects are prohibited. Before-and-after images must not mislead about effects. The sixth-edition examples reject subjective patient experience as a substitute for adequate risk information.
For self-pay treatment, explain usual treatment content, duration and sessions, standard cost, and principal risks and adverse effects. Patient consent alone does not make prohibited advertising lawful.
Sources: Medical advertising case explanations, sixth edition, March 2026 · Sixth edition, March 2026; case 28 and patient-experience examples
Channel rules
Check the complete consumer-facing message
Regulator guidance
The misleading-representations regime covers goods and services, including misleading impressions about quality or price advantages. Review the full presentation and offer conditions. A truthful individual detail does not justify a deceptive overall claim.
Sources: Establishing Trusted Representation
Advertiser-directed content must be recognisable as advertising
Regulator guidance
CAA’s stealth-marketing rule addresses a supplying advertiser involved in determining a representation whose commercial nature consumers cannot recognise. Assess the brand’s role in the content and the overall presentation, including commissioned posts and reviews.
An influencer acting only as the commissioned publisher is generally not the regulated advertiser under this particular designation; CAA identifies joint supply of the product as an exception. This does not exempt the content from product-advertising law or other duties.
Sources: Stealth marketing regulation from 1 October 2023; CAA — Stealth marketing questions and answers · CAA stealth-marketing FAQ Q1
Review the spoken promotion
Editorial recommendation
Assess the host-read wording and audible identification within the recording. Do not assume listeners will open show notes. Decide whether a filmed or broadcast version needs a separate review.
Campaign workflow
Medical Treatments & Services: prepare the review
Editorial recommendation
Define the actual treatment and who is authorised to provide it. Separate evidence of a possible benefit from a promise of an individual result. Explain material limits, costs and eligibility without creating pressure for unnecessary care.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Define the actual treatment and who is authorised to provide it.
- Separate evidence of a possible benefit from a promise of an individual result.
- Explain material limits, costs and eligibility without creating pressure for unnecessary care.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- March 2026 sixth-edition medical advertising examples, website exemption conditions and FFC transitions have been checked. Remaining checks concern prefectural implementation, practitioner-specific and pharmacy requirements, actual product notifications and treatment disclosures, personal-information processing and each messaging technology. This pack does not supply every Japanese mandatory warning text.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
Promoting a medical treatment in podcasts and digital audio in Japan requires a precise description of the service and who provides it. Connect the evidence for possible benefits with realistic patient expectations and the applicable professional advertising conditions.
Podcast listeners may hear a promotion without seeing its show notes. Assess audible commercial identification, the host's statements and required spoken information in the recording itself; a filmed podcast also needs a visual-format review.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Japanese product and medical-service advertising baseline; local and product-specific implementation requires review. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- MHLW: advertising restrictions for hospitals and clinics
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Medical advertising case explanations, sixth edition, March 2026
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- Establishing Trusted Representation
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Stealth marketing regulation from 1 October 2023
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- CAA — Stealth marketing questions and answers
Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.
From framework to action
Local expertise in Japan
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Japan.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.